MiNK Therapeutics (INKT) News Today $10.18 +0.32 (+3.29%) Closing price 02/21/2025 03:58 PM EasternExtended Trading$9.86 -0.33 (-3.23%) As of 02/21/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period MiNK Therapeutics voldoet weer aan Nasdaq-noteringseisenFebruary 20 at 12:27 PM | nl.investing.comMiNK Therapeutics Regains Full Compliance with Nasdaq Listing RequirementsFebruary 20 at 12:27 PM | finance.yahoo.comMiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual MeetingFebruary 12, 2025 | globenewswire.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Sees Significant Increase in Short InterestMiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 123,000 shares, an increase of 160.6% from the December 31st total of 47,200 shares. Based on an average daily trading volume, of 96,700 shares, the days-to-cover ratio is currently 1.3 days. Currently, 1.2% of the company's stock are sold short.January 29, 2025 | marketbeat.comMiNK Therapeutics (NASDAQ:INKT) Stock Quotes, Forecast and News SummaryJanuary 28, 2025 | benzinga.comMink Therapeutics Inc trading halted, news pendingJanuary 28, 2025 | markets.businessinsider.comMink Therapeutics stock hits 52-week high at $8.84January 28, 2025 | msn.comMiNK Therapeutics presenteert kankerstudie op ASCO GIJanuary 24, 2025 | nl.investing.comMiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GIJanuary 23, 2025 | globenewswire.comMiNK Therapeutics announces reverse stock splitJanuary 21, 2025 | msn.comMiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual MeetingDecember 18, 2024 | globenewswire.comMiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...November 18, 2024 | ca.finance.yahoo.comMiNK Therapeutics Reports Q3 Growth and Strategic AdvancesNovember 16, 2024 | markets.businessinsider.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | msn.comResultaten conference call: MiNK Therapeutics slaagt erin kosten met 60% te verlagenNovember 15, 2024 | nl.investing.comQ3 2024 Mink Therapeutics Inc Earnings CallNovember 15, 2024 | uk.finance.yahoo.comPromising Developments in MiNK Therapeutics Drive Buy RatingNovember 15, 2024 | markets.businessinsider.comExamining the Future: MiNK Therapeutics's Earnings OutlookNovember 14, 2024 | benzinga.comMiNK Therapeutics Reports Third Quarter 2024 Results and Business UpdateNovember 14, 2024 | markets.businessinsider.comMiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call TranscriptNovember 14, 2024 | seekingalpha.comMiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial ReportNovember 11, 2024 | globenewswire.comMiNK Therapeutics presents data on iNKT cell therapy programsNovember 7, 2024 | markets.businessinsider.comMiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024November 7, 2024 | finance.yahoo.comMiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024November 7, 2024 | globenewswire.comMiNK Therapeutics Appoints Dr. Robert Kadlec to BoardOctober 31, 2024 | markets.businessinsider.comMiNK Therapeutics appoints Robert Kadlec to board of directorsOctober 31, 2024 | markets.businessinsider.comMiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of DirectorsOctober 31, 2024 | globenewswire.comMiNK Therapeutics aandeel stijgt door nieuwe RNA-samenwerking met AutonomousOctober 9, 2024 | nl.investing.comMiNK Therapeutics Inc (INKT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...October 9, 2024 | finance.yahoo.comMiNK, Autonomous Partner To Develop Novel Therapies Targeting Metastatic TumorsOctober 8, 2024 | markets.businessinsider.comMiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic TumorsOctober 8, 2024 | globenewswire.comMiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024October 4, 2024 | globenewswire.comMiNK Therapeutics faces potential Nasdaq delistingSeptember 15, 2024 | investing.comMiNK Therapeutics to Participate in H.C. Wainwright Global Investment ConferenceSeptember 3, 2024 | globenewswire.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | msn.comWinstgesprek: MiNK Therapeutics rapporteert vooruitgang Q2 2024August 14, 2024 | nl.investing.comMiNK Reports Second Quarter 2024 Results and Business UpdateAugust 13, 2024 | globenewswire.comMiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial ReportAugust 1, 2024 | globenewswire.comMiNK Therapeutics voldoet aan de kapitaalvereisten van NasdaqJuly 31, 2024 | nl.investing.comMiNK Therapeutics Regains Compliance with Nasdaq Capital Market RequirementJuly 31, 2024 | globenewswire.comMiNK Therapeutics Announces Virtual Annual Shareholders MeetingJune 5, 2024 | globenewswire.comMiNK Therapeutics: MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual MeetingMay 22, 2024 | finanznachrichten.deMiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual MeetingMay 22, 2024 | globenewswire.comQ1 2024 Mink Therapeutics Inc Earnings CallMay 15, 2024 | uk.finance.yahoo.comMiNK Therapeutics Inc (INKT) Q1 2024 Earnings Call Transcript Highlights: Strategic Reductions ...May 15, 2024 | finance.yahoo.comINKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024May 14, 2024 | investorplace.comMiNK Reports First Quarter 2024 ResultsMay 14, 2024 | globenewswire.comMiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board ObserverMay 13, 2024 | globenewswire.comMiNK to Provide Corporate Update and First Quarter 2024 Financial ReportApril 30, 2024 | finance.yahoo.comMiNK to Provide Corporate Update and First Quarter 2024 Financial ReportApril 30, 2024 | globenewswire.com Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address INKT Media Mentions By Week INKT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INKT News Sentiment▼0.000.60▲Average Medical News Sentiment INKT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INKT Articles This Week▼21▲INKT Articles Average Week Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Instil Bio News Today Lexeo Therapeutics News Today Adaptimmune Therapeutics News Today Sutro Biopharma News Today Silence Therapeutics News Today Seres Therapeutics News Today Puma Biotechnology News Today Coherus BioSciences News Today Biomea Fusion News Today Black Diamond Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INKT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
